TITLE

Biovail files NDA for novel dosage form of anti-depressant

PUB. DATE
July 2004
SOURCE
PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p12
SOURCE TYPE
Market Research Report
DOC. TYPE
Article
ABSTRACT
Reports on the acceptance of the U.S. Food and Drug Administration to Biovail Corp.'s submission of a new drug application for a novel dosage format of citalopram for the treatment of depression. Product offering; Characterization of citalopram hydrobomide; Market penetration of citalopram.
ACCESSION #
13856088

 

Related Articles

  • Biogenerics market presents new commercial opportunity.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p22 

    Assesses the market potential of biogenerics in the pharmaceutical biotechnology industry in the U.S. Growth of the demand for biogenerics; Factors affecting the faster approval process for biogeneric drugs; Opposition of the biotechnology industry against the U.S. Food and Drug Administration'...

  • FDA approves Eli Lilly's Zyprexa in bipolar I disorder.  // PharmaWatch: CNS;September 2003, Vol. 2 Issue 9, p12 

    Reports on the approval of the U.S. Food and Drug Administration to Eli Lilly & Co.'s Zyprexa antidepressant as a combination therapy in bipolar I disorder. Basis for the regulatory decision; Safety and efficacy of Zyprexa; Response of patients taking Zyprexa.

  • Biovail shares depressed on Wellbutrin generic filing.  // PharmaWatch: CNS;January 2005, Vol. 4 Issue 1, p10 

    Reports that Biovail Corp.'s shares have hit a one-year low after it confirmed that Anchen Pharmaceuticals company had submitted an abbreviated new drug application to the U.S. Food and Drug Administration to market a generic version of antidepressant medication Wellbutrin XL. Formulations of...

  • GlaxoSmithKline receives FDA approvable letter for Wellbutrin XL.  // PharmaWatch: CNS;August 2003, Vol. 2 Issue 8, p10 

    Reports on the approval of the antidepressant Wellbutrin XL tablets of GlaxoSmithKline PLC by the U.S. Food and Drug Administration. Increase in the treatment options for adults with depression; License agreement between the firm and Biovail Corp.; Efforts of the company to work with the agency...

  • FDA grants priority review to Gilead's HIV co-formulation.  // PharmaWatch: Biotechnology;July 2004, Vol. 3 Issue 7, p13 

    Reports on the approval of the U.S. Food and Drug Administration to Gilead Sciences Inc.'s New Drug Application for the fixed dose co-formulation of the anti-HIV medications Viread and Emtriva. Terms under the priority review; Designation granted to drugs; Administration of the proposed...

  • ImClone wins FDA approval for Erbitux.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration (FDA) to ImClone Systems Inc.'s Erbitux designated to treat advanced colorectal cancer. Impact of the approval of the FDA on the operation of the company; Evidence showing the safety and efficacy of Erbitux; Response of patients...

  • FDA approves Amgen's drug for chronic kidney disease.  // PharmaWatch: Biotechnology;April 2004, Vol. 3 Issue 4, p13 

    Reports on the approval of the U.S. Food and Drug Administration to Amgen Inc.'s Sensipar drug targeting chronic kidney disease. Classification of Sensipar; Safety and efficacy of the drug; Response of patients taking Sensipar.

  • Cardizem LA.  // Formulary;May2004, Vol. 39 Issue 5, p239 

    Provides information on Biovail Corp.'s extended-release calcium antagonist Cardizem LA, which has been approved by the U.S. Food and Drug Administration for the treatment of chronic stable angina.

  • Extended-Release Metformin Combo Drug Given the Green Light. Trecroci, D. // Diabetes Health;Dec2005, Vol. 14 Issue 12, p19 

    Reports on the approval of the drug Glumetza, a formulation of metformin hydrochloride manufactured by Biovail, by the U.S. Food and Drug Administration. Use of the drug for the treatment of type 2 diabetes; Potential advantages of the drug; Common side effects of the drug.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics